RESOURCES
Helpful resources
For your practice
Download this brochure to learn more about the benefits of ZILBRYSQ and how to initiate treatment for your patients.
Guide to Writing a Letter of Appeal
Download for information about creating a letter of medical appeal. Includes sample letter for reference.
Guide to Writing a Letter of
Medical Necessity
Download for information about creating a letter of medical necessity. Includes sample letter for reference.
Prior Authorization/
Predetermination Checklist
Download this checklist as an educational resource regarding common prior authorization requirements for ZILBRYSQ.
For your patients
Use this form to get your patients started with ONWARD.
Provide your patients with this guide to help them learn more about ONWARD personalized support.
Direct your patients to this brochure to help them understand the benefits of ZILBRYSQ and how it works.
Helps patients learn how the MG-ADL score assesses gMG.
Ensure your patients have access to the Instructions for Use before getting started with ZILBRYSQ.
Learn about Medicare Part D changes for 2025
Media library
ZILBRYSQ Mechanism of Action (MOA) video
See how ZILBRYSQ, a C5 inhibitor, specifically targets the complement cascade, preventing the assembly and activity of the membrane attack complex.1,2
The precise mechanism through which ZILBRYSQ exerts therapeutic effects in gMG is unknown.1
ZILBRYSQ Injection Training video
Watch a step-by-step demonstration of the proper self-administration of ZILBRYSQ.
ZILBRYSQ: A Clinically Proven Choice
RAISE and RAISE-XT Clinical Studies
Listen to Dr Michael Weiss, an expert in gMG, discuss the RAISE clinical studies with a focus on the primary endpoints of MG-ADL total score and long-term safety and tolerability.
ZILBRYSQ: A Targeted Choice
How ZILBRYSQ specifically targets the complement cascade
Watch Dr Hannah Machemehl, an expert in gMG, discuss how ZILBRYSQ provides complement inhibition.
References:
- ZILBRYSQ [Prescribing Information]. Smyrna, GA: UCB, Inc.
- Howard JF Jr, Bresch S, Genge A, et al; RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7
